Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

This study is currently recruiting participants.

Verified by University of Colorado, Denver, April 2007

First Received: March 23, 2007 Last Updated: April 6, 2007 History of Changes

Sponsor:	University of Colorado, Denver
Information provided by:	University of Colorado, Denver
ClinicalTrials.gov Identifier:	NCT00452283

Purpose

There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss.

We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.

Condition
Glaucoma Pulmonary Hypertension

Study Type:	Observational
Study Design:	Cross-Sectional, Defined Population, Prospective Study
Official Title:	The Effect of a Systemic Non-Selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure Pulmonary Hypertension

U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Estimated Enrollment:	100
Study Start Date:	March 2007

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

diagnosed with pulmonary hypertension
between the ages of 18 and 80 years
ability to undergo the various ocular exams.

Exclusion Criteria:

patients with other diseases that could affect the nerve fiber layer
specials populations; ie children, pregnancy, lactating females, prisoners

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452283

Contacts

Contact: Tim Byrne	720-848-5051	tim.byrne@uchsc.edu
Contact: Malik Y. Kahook, M.D.	720-848-5029	malik.kahook@uchsc.edu

Locations

United States, Colorado
Rocky Mountain Lions Eye Institute	Recruiting
Aurora, Colorado, United States, 80045
Contact: Tim Byrne 720-848-5051 tim.byrne@uchsc.edu
Contact: Malik Y. Kahook, M.D. 720-848-5029 malik.kahook@uchsc.edu
Principal Investigator: Malik Y. Kahook, M.D.
Sub-Investigator: Naresh Mandava, M.D.
Sub-Investigator: David B. Badesch, M.D.
Sub-Investigator: Douglas L. MacKenzie, M.D.

Sponsors and Collaborators

University of Colorado, Denver

Investigators

Principal Investigator:

Malik Y. Kahook, M.D.

University of Colorado School of Medicine

More Information

No publications provided

Study ID Numbers:	myk06-0792
Study First Received:	March 23, 2007
Last Updated:	April 6, 2007
ClinicalTrials.gov Identifier:	NCT00452283 History of Changes
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Respiratory Tract Diseases
Hypertension, Pulmonary
Glaucoma
Lung Diseases
Eye Diseases

Vascular Diseases
Cardiovascular Diseases
Ocular Hypertension
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010